I'm on a clinical trial with Johnson and Johnson. I started 1-2-24 and am on Talvey & Dara. I had some reactions when first introduced but they have subsided and I'm MRD Negative since 1-2-25
July 14
Good luck on your treatment decisions Darlene. I'm glad we have options,
July 14
Wonderful! That's great news!
July 14
I just started bispecific yesterday. I looked thoroughly at both and am more enthusiastic about this than about CAR-T. It is TECVAYLI + FASTPRO, just approved Mar 5, 2026 after a 3 year clinical trial with 83% response rate. Trains your T-Cells in your body rather than with removal, It may depend on where you are going to get your treatment I guess.
Wishing you well,
Leland
July 14
That's a big and exciting step in your myeloma journey! While personal experiences can't be shared here, what's known from MyMyelomaTeam members and research can help paint a picture of both options.
Both treatments work by using your immune system to target and destroy myeloma cells, but they go about it differently.
CAR Show Full Answer
That's a big and exciting step in your myeloma journey! While personal experiences can't be shared here, what's known from MyMyelomaTeam members and research can help paint a picture of both options.
Both treatments work by using your immune system to target and destroy myeloma cells, but they go about it differently.
CAR T-Cell Therapy (e.g., Abecma or Carvykti)
- Your own T cells are collected, genetically modified in a lab, then infused back into your body
- Targets a protein on myeloma cells called BCMA
- Can produce deep, long-lasting remissions — even after many prior treatments
- Requires planning ahead due to cell collection and manufacturing time
- Only available at specialized treatment centers Bispecific Antibodies (e.g., Teclistamab)
- Also targets BCMA, but works by linking your T cells directly to myeloma cells
- No cell collection needed — treatment can start more quickly
- Given on an ongoing basis rather than as a one-time infusion
Potential side effects for both include:
- Cytokine release syndrome (CRS) — fever, low blood pressure, fatigue
- Increased infection risk
- Neurological issues (more associated with CAR T)
Both are promising options, especially for relapsed or refractory myeloma. Talking openly with your oncologist about your specific situation, health history, and goals will help determine which path makes the most sense for you.
July 13
Join
Your Privacy Choices
